Systemic lupus erythematosus
The rate of SLE varies between countries, ethnicity, and sex, and changes over time. In the United States, one estimate of the rate of SLE is 53 per 100,000; other estimates range from 322,000 to over 1 million. In Northern Europe the rate is about 40 per 100,000 people. SLE occurs more frequently and with greater severity among those of non-European descent. That rate has been found to be as high as 159 per 100,000 among those of Afro-Caribbean descent. Childhood-onset systemic lupus erythematosus generally presents between the ages of 3 and 15 and is four times more common in girls.
GlySens ICGM
Science Translational Medicine reported success on long-term glucose monitoring with the sensor-telemetry system implanted in the tissues of pigs. Monitoring was carried out while the pigs were initially non diabetic and continued for 6 months after the pigs had been made diabetic by administration of a laboratory drug. The long-term animal results reported by David Gough provide a foundation for human trials, which began in January, 2015 and is expected to conclude in early 2016.The first round of human trials includes a group of 20 individuals, both male and female, from the age of 21 to 65 years old. Each subject was implanted with the GlySens ICGM monitor under the skin of the upper arm and monitored over the course of 18 months. The GlySens ICGM system is currently undergoing clinical evaluation, the initial human implant trials have been completed, and preparations for additional human trials are underway.In 2014 worldwide, an estimated 382 million people had diabetes, and this number is expected to double by the year 2030. In the United States alone, nearly 29 million people have been diagnosed with diabetes, and an additional 79 million people are classified as pre-diabetic. The World Health Organization projects that diabetes will be the 7th leading cause of death in 2030. The worldwide annual expenditure on home and self blood glucose monitoring products has been estimated at $7 to $10 billion with half of the sales occurring in the U.S. The total economic impact of diabetes in the U.S. is estimated at $245 billion each year.